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Outcome of human islet isolation and 
allotransplantation in 20 consecutive cases 
C. Ricol'di'. P. CarroW. A. Tzakis·. Y. Zeng*. H.L.R. oilo~K R. Alejandro". R. Shapiro**. J.J. Fung', 
AJ. Demetris'. D.H. Mintz'''* and T.E. Starzl* 
.lBSTRACT. This report provides our initial experience on islet isolation and intrahepatic allotrans-
plantation in 20 patients. In Group 1. 10 patients underwent combined liver-islet allotransplantation 
followin1! upper-abdominal exenteration for cancer. One patient underwent pancreatic islet allograft 
after nt'ar total pancreatectomy for chronie pancreatitis. In Group 2, 3 Type I diabetic patients received 
a \,ombint·d livI'I'-islet allograft for cirrho!oii!oi and diabetes. In Group 3. 7 Type I diabetic patients re-
(·piwd 8 ('ombined cadaveric kitlney-i!oilet 1!rafts (one retransplantl for end stage renal disease. The islets 
'WI't' ~itDparated hy a modification of the automated method for human islet isolation and the preparations 
wI're infust'd into the portal vein. Immunosuppression was with FK-506 (Group 1) plus steroids (Groups 
:! anti :~FK ::-iix patients in Group 1 did not require insulin treatment for 5 to >16 mo. In Groups 2 and 
:~ nonp of thl' patients beeame insulin-independent. although ongoing C-peptide secretion. decreased 
insulin rpquirement and stabilization of diabetes were ohserved. Our results indicate that islet trans-
plantation is most effective in pancreatectomy induced diabetes. However. rejection is still a major fac-
tm' limiting thl" clinical application of islet transplantation in patients with Type I diabetes mellitus. Oth-
t'r fae10rs such as steroid treatment may contribute to deteriorate islet engraftment and/or function. 
INTRODUCTION 
Type [ diabetes is an autoimmune disease with seri-
ous lon~-term complications including retinopathy 
lhat can lead to blindness. neuropath\'. nephropathy. 
Illacro\'as('ular disease and a limited life span (1-3). 
In patients wilh Type I diabetes mellitus. insulin pro-
duction by the pancreatic islets progressivelv de-
dines and finally disappears. as the f3-cells within 
the islets are destroyed by an autoimmune process 
resulting from a complex interplay between genetic 
and unknown environmental factors (4). Replacement 
therapy with exogenous insulin is imperfect and has 
been ineffective in preventing the chronic complica-
tion of the disease. Thus. alternative methods for total 
endocrine replacement have been explored. includ-
ing transplantation of isolated islets as free grafts (5). 
1990 was a significant year for clinical islet trans-
plantation. since after many attempts, reports of short-
term (6) and prolonged (7-11) insulin-independence 
following human islet allotransplantation. indicated 
that it is possible to replace the endocrine function of 
the pancreas by an islet transplant in man. The de-
velopment of improved procedures for islet isolation 
and purification from large animals (12-16) and hu-
man (17-22) pancreata have resulted in significant 
progress in both the number and purity of islets that 
can be obtained from each pancreas. In addition. the 
use of more powerful immunosuppressive agents such 
as cyclosporine A (6.8.21) or FK-506 (7.11) resulted 
in prolonged human islet allograft survival in some 
cases. This report summarized our initial experience 
on islet isolation and intrahepatic allotransplantation 
in 21 patients. 
MATERIALS AND METHODS 
Patients 
Twenty-one intrahepatic islet allografts were per-
formed in 20 patients between 10 January. 1990 and 
4 May, 1991 (11). 
Group 1: Ten patients aged 8-58 yr underwent com-
bined liver-islet allotransplantation following upper-
abdominal exenteration for tumors too extensive to 
be removed with less drastic procedures (23.24). More 
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detaileJ results on nine of these patients have been re-
ported previously (7). Liver. pancreas. spleen. stom-
ach. duodenum. proximal jejunum. terminal ileum. 
ascending and transverse colon (three cases t. and 
part of the right atrium (one case, was removed. A 
eadaveric orthotopic liver allograft was done (24) and 
the ~raft portal vein was anastomosed to the recipient 
superior mesenteric vein. Arterialization were from the 
recipient aorta or celiac axis. A 14G catheter with a 
heparin lock was placed in a superior mesenteric vein 
(7). Bowel continuity was reelitablished and bi liarv 
draina~e was via a choledocojejunoslomv. One pa-
[it'nl had near total pancreatectomy for pain rplief 
due to chronic pancreatitis and had an auto~raft of 
isle!:; ohtained from the pancreas. 
(;roujI 1: 'I1lfee Df~Dpe I diabetic patients aged 22-56 vr 
n-Teivf'd a combined liver-islet allo~raftK The indica-
I ions {(Ir liver transplantation were {'irrhosis secondary 
to hepatitis C. alcoholic cirrhosis and cryptogenic 
cirrhosis. 
Group ,'$: Seven patients aged 28-42 yr receivpd 8 
('ombined cadaveric kidney-islet ~rafts (one retrans-
planO for end stage renal disease secondary to Type 
I diahetes mellitus. Immediatelv after renal trans-
plantation. an upper midline incision was performed 
and a 16-18G catheter was placed in a jejunal vein for 
islet infusion. All patients had negative C-peptide in 
response to a Sustacal challenge test perfonned before 
islet transplantation. 
Organ procurement 
The E~adaveric donor ABO types were the same as. 
or compatible with the recipient ABO types. HLA 
matching was random and the antigen match was 0 to 
:~K There were two positive cytotoxic cross-matches 
in Group I (Cluster-Islet) and two in Group 2 (Liver-
Islet). The livers. kidneys and pancreases were ob-
tained from multi-organ donors (23-25). In situ per-
fusion of the abdominal aorta was with 1500-2000 
tnl of University of Wisconsin solution (UWS). An 
additional 500-1000 ml of UWS were infused directly 
into the liver via the portal vein. which was enci;-
ded below the catheter tip to prevent retrograde leak-
age. Venous hypertension of the pancreas was avoid-
ed by venting the portal and/or splenic vein. The 
specimens were immersed in UWS and packed on 
ice. The pancreas of the liver or kidnev donor was 
the source of the primary islet graft for all patients ex-
cept one patient in Group 1 and one patient in Group 
:3 who received islets from a third party pancreas 
194 ONM. Vol. 5. Suppl. 1 
donor. Four patients in Group 1 and two patients in 
Group 3 were given islets from 1-2 additional donors 
1-5 days after the principal operation. One patient 
in Group 3 was retransplanted (Kidnev-Islet) seven mo 
after the first combined graft because of irreversible 
kidney rejection. 
Islet preparation and administration 
Cold ischemia time of the 28 pancreases averaged 
7.5 hr (range 4-12) with no statistically significant 
difference between groups. The human islets were 
obtained bv a modification (15) of the automated 
method for human islet isolation (18). Brief1v. after 
cannulation of the pancreatic duct 350 ml of Hanks 
solution containing 2 mg/ml collagenase solution 
(Boehringer-Mannheim. Type P) was injected through 
the duct. The pancreas was loaded into a stainless 
~teel digestion chamber and islets Wf're separated 
during a continuous digestion process that lasted 30-
45 min. The main modifications of the isolation pro-
cedure compared to the previously described auto-
mated method (18) were the volume of the isolation 
chamber that is now of 475 ml with an outlet port di-
ameter of 6 mm. and the pore size of the screen that 
was increased from 280 to 400 !J. The cooling sys-
tem as well as the heating circuit bypass were elim-
inated. resulting in a simpler isolation apparatus (1). 
During the recirculation phase (flow rate 85 mUmin) 
intrachamber temperature was increased at a rate of 
2°C/min by passage of the solution through a stainless 
steel coil immersed in a water bath ISO°C). The cham-
ber containing the distended pancreas was gently ag-
itated and samples were taken every 2 min to moni-
tor digestion. After approximately 20-30 min of re-
circulation the digestion was stopped by dilution (4°C 
Hanks. 400 mUmin flow rate) and cooling. The dilu-
tion phase lasted 15-20 min. Upon initiation of the di-
lution phase the chamber was connected to a shaker 
with oscillation amplitude of 10 cm and a variable 
rate of 0-320 oscillation/min. Eurocollins solution 
was used as vehicle for the Ficoll powder (Ficoll DL-
400. Sigma. 51. Louis MO). Eurocollins-Ficoll at den-
sities of 1.108. 1.096. 1.037 was used in a three lay-
er discontinuous gradient (10). in which the digested 
pancreatic tissue was bottom-loaded with the 1.108 
layer. A cell separator (COBE 2991. Lakewood. CO) 
was used for centrifugation of the gradients (26.27). 
Determination of number, volume and purity of the hu-
man islets obtained after islet separation and purifi-
cation was performed according to recently proposed 
t 
'. 
I. 
I~ 
criteria (28). The final preparation was pelleted and 
suspended in 100 ml Hank's solution containing 10% 
human albumin and infused into the portal vein 
catheter over 20-30 min. Portal venous pressure was 
measured and in some cases the portal flow was as-
sessed bv color doppler ultrasono/!raphy. In patients 
who receiveo more than one islet preparation. the 
portal vein catheter was flushed every 6 hr with 2 Illi 
saline containing heparin ~ 100 Ulrlli). The catheter was 
removed after completion of the last islet infusion. 
Immunosuppressil'l' management 
In Group I. immunosupprFssion with FK-.,)()6 hc~an 
with intravenous doses of 0.07.') fll~kg every 12 hI' 
'f'ol\owed bv 0.1;') mg/kg orallv F\Prv 12 hr. Tlw <lost' 
\Ias adju>ited on clinical grounds and bv monitoring 
plasma FK-;")06 levels. The patient \Iith the autograft 
did not receive anv immunosuppressioll. In Croup 2. 
FK-506 was administered at a dose oflK11l1~/kg i.v. 
over 24 hr, beginning immediatelv after transplanta-
tion. In adoition. the patients recei ved a 1000 mg i. v. 
bolus of methylprednisolone durin~ the operation. 
followed by a maintenance dose of 20 mg preonisolone 
IV dailv. until conversion to the oral route. The oral 
dose of FK-506 was 0.15 mw'kg every 12 hr (0.3 mg/kg 
per day), and 20 mg of prednisone per day were giv-
en. This dose was reduced and discontinued accord-
ing to clinical criteria. In Group ;). FK-506 was given 
as in Group 2. Following the intraoperative i.v. bolus 
of 1000 mg methylprednisolone. a oecreasing pred-
nisone dose (from 200 to' 20 mg/dav) was adminis-
tered over 6 days. When possible. the steroid dose 
was tapered over the first several wk and stopped. 
Supplementary steroids or OKT3 was given if rejection 
was suspected clinically or diagnosed by biopsy. 
Pre-transplant assessment of recipient islet function 
Basal and stimulated plasma C-peptide levels were 
measured in all recipients before the infusion of the 
islets. The provocative tests were 1 mg glucagon i. v. 
(Group 1) and a Sustacal (6 Kcallkg) (29) or glucagon 
(Groups 2 and 3) challenges. All patients had absent 
C-peptide responses preoperatively except for the pa-
tient with the autograft. 
Post-transpLant assessment of dorwr islet function 
After islet transplantation. plasma glucose and C-
peptide levels were monitored. An intravenous glucose 
tolerance test (lVGTr), was used as provocative test 
of C-peptide secretion in patients in Group 1. IVGTT 
was chosen to avoid interpretative problems in the 
evaluation of the results. since the patients of this 
group underwent significant gastrointestinal resec-
tions. In groups 2 and 3. a Sustacal tolerance test 
(SIT) was selected as provocative test of C-peptide se-
(,retion. Glycosvlated haemoglobin (HbA1.J was mea-
"ured before and every 6 wk after transplantation. or 
when the patients were evaluated in follow-up clinics. 
RESULTS 
Islet isolation and purification 
Pancreas cold ischemia time Ie IT) before the islet 
i,.;olation and purification procedure was comparable 
ill tilt' three groups. ranging 4 to 12 hr. In Group 1. the 
1··~ human isld preparations that were transplanted 
('omprised an average of 392.100 isldS. represent-
ing an average of 279.800 lEq with an endocrine vol-
lime of approximatelv 495 Ill. Purity in islets was 
61 % (range 25-80%). In Group 2. 3 islet prepara-
tions vielded an average of over 800.000 islets. rep-
resenting 625.300 lEq. Average endocrine volume 
and purity in islets were 1.105 ul and 67% respec-
tively. In Group 3. 11 islet isolations resulted in an av-
erage of 644.600 islets (597.000 IEq) with an en-
docrine volume of 1.055 ~K The average purity in 
islets was 72%. Patients in groups 2 and 3 received 
a number of islets that was significantly higher 
(p<0.05) compared to the cluster-islet patients of 
Croup 1. No significant difference was observed in the 
degree of puritv in islets infused in the three groups. 
and in the number of islets transplanted in Groups 2 
and 3. 
Patient survival 
Following our preliminary report on cluster-islet al-
lotransplantation (7). two additional patients died 
from cancer recurrence 9 and 14 mo following trans-
plantation.leaving 5 of 10 patients in Group 1 with fol-
low-up of 16. 14. 13. 13. and 1 mo. In Group 2 (n=3), 
one patient died 36 hr following combined liver-islet 
transplantation. The patient had a positive cross-
match (100%) with her liver-islet donor and had pri-
mary hepatic non-function because of humoral (hy-
peracute) rejection. A second patient. who demon-
strated significant islet function for the first 5 post-op-
erative mo. died of hepatitis B and sepsis 6 mo after 
transplantation. In Group 3 (n=7), one patient died of 
aspiration pneumonia 5 days following combined kid-
nev-islet transplantation. 
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Post-transplant islet function 
In Group 1. six patients did not require insulin for;) 
10 0\ er 16 mo. The first patient. "ho recei ved the 
i,;[et allo/!raft on 10 January. 1990. i" ,,[ill insulin-in-
dependent over 18 mo post-operatively. Neverthe-
less. 9 rno after transplantation the average value of 
pre- and post- prandial blood glucose determinations 
progres,;ivdy increased until the I-1th postoperative 
mo. but has spontaneously improved durin/! the last 
120 davs. It is of intere,;t that this patient required over 
:tOOO and 2.000 U of intravenous in;;ulin on her fourth 
and fifth post-operative day respet'ti\t'ly. This is the 
1II0st insulin we have used in al1\ patienl in the ;~ 
~roupsK Two patients who n"('enth died 01 tumor re-
"IIlT('n('e did nol require insulin at the lime of r('cur-
tt'lice alld e\pired with frfllDlionin~ hlet grafts 9 and 
1+ nlO atter transplantation. In (Jlle patient (No.6) 
who \\as insulin-dependent (71. the islet funl'lion P11)-
f!:ressively improved and insulin treatment was dis-
continued during the third post-opprative 1110. ~he 
did not require insulin for ;) mo. Insulin treatment 
was resumed 8 mo after islet allotran;;plantation (2.5-
L L L/day. s.c., for increased fasting plasma glucose 
lpvels (> 120 middl). The patient lIas converted to 
oral hvpoglycemic a/!ents (/!libendamide 5 mg/day) 14 
mo after transplantation. since her insulin require-
ment was minimal. She on('e again dops not require in-
~ulinK One patient j No. H). did not require davtime 
insulin treatment. but was unable to discontinue night 
parenteral nutrition dO U ofinsuJin/night. i.v.). One 
patient (No.9). did not require insulin until the 10th 
post-operative mo. when sudden development of svmp-
tomatic hyperglycemia in the absence of any evidence 
of liver rejection imposed reinstitution of exogenous 
insulin treatment. The patient with the autograft does 
not require exogenous insulin but pancreatectomy 
was not total. 
In Group 2. one patient is alive 1 yr after transplan-
tation. She had a 100% positive cvtotoxic cross-match 
and a rejection episode during th~ first post-operative 
week. Approximately 80% decrease in her insulin 
requirement was observed over the first 6 post-oper-
ative IllO ifrom 70 to 15 (J of insulin per day) (11). It 
was evident that glycemic control was extremelv sta-
ble con~p~red to preoperative values and HbA;( has 
been wlthm the normal range «5.9%). In addition. 
:Sustacal challenge tests 2. 3 and 6 mo after trans-
plantation have shown progressive improvement of 
plasma C-peptide. A delay in C-peptide secretion 
alld prolonged elevation during the challenge was ev-
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ident in this patient. as previously reported in recip-
ients of cluster islet grafts (7). The second patient. 
who died 6 mo after transplantation from hepatitis 13 
and sepsis. also demonstrated significant islet func-
tion. His insulin requirement rapidly decreased dur-
ing the first three post-operative wk. A rejection 
episode on wk 4 imposed a significant increment in 
the daily insulin dose. that never returned to pre-re-
jection levels. The islets were not completely reject-
t'd as documented by persistence of significant basal 
and stimulated C-peptide levels of 0.76 and 1.59 pM 
respectively iSustacal challenge. :2 tno post-trans-
planO. 
In Group ;). no patients became insulin-indepemlent. 
\Il patients had at least one rejection episode in the 
lirst post-operative mo. One patient lost the trans-
planted kidney due to rejection. Of interest in this 
patient was documentation of islet function with basal 
and stimulated C-peptide of 0.30 and 0.75 pM re-
spectively. after the kidney was completely rejected. 
The patient received a second kidnev-islet graft 6 mo 
after the first combined transplant. but never became 
insulin-independent despite receiving the highest 
number of islets i>2.000.000 IEq) in the study. C-
peptide was measurable in all cases. although only 
three of six patients with a follow-up of more than 
one mo had significant basal and stimulated plasma 
C-peptide (basal = 1.62/0.;)6/0.3B and peak = 
1.95/0.57/0.93 pM) following a :Sustacal challenge 
test 4-8 wk post-operatively. Two patients had 48% 
and 70% reduction in insulin requirements follow-
ing transplantation. It is of interest that basal and 
stimulated C-peptide levels in both cluster-islet and 
liver-islet groups were higher compared to kidney-
islet recipients (11). Diabetes was stabilized in all 
patients, despite they all had at least one episode of 
rejection confirmed on biopsy. 
DISCUSSION 
Several cases of intrahepatic human islet allografts 
have been recently reported (6-9) with transient (8) or 
prolonged (7-9) insulin independence. Two patients 
with Type 1. insulin-dependent diabetes mellitus (8,9) 
received islets from multiple donors (4 and 5 pan-
creases). One of these patients (9) was still insulin-in-
dependent one yr after islet allotransplantation. In 
the present report, prolonged (5 to > 16 mo) insulin-
independence was observed in 6 patients who un-
derwent upper abdominal exenteration and liver-islet 
repiacement i 7). Four of them recei vetl islets from 
two donors. The first patient of this series is still in-
sulin-independent over 16 rno after the islet allograft 
and received islets from a single donor. In contrast. in 
our experience none of the Type I diabetic patients 
who reecived either a liver-islet or a kidnev-islet al-
lograft are insulin-independent. Although our best 
result in Type I diabetic patients was obtained in a 
case of positive cross-match (100%). lIe currently 
consider a positive cross-match as an absolute con-
traindication to human islet allotransplantation. Oil:" 
ferences in islet isolation an%r purification tech-
I'iqw-'s do not explain the inferior results ohtained in 
tilt-' ('ollliJined kidney-i:.;let group. :.;inee the patient:.; in 
lIle three group:.; wprest-'nl eonse('utin-' ("uses in \\ hi('h 
I!II-' sallie separation and purification procedures lIen" 
used for human islet isolation. Possible explanation,; 
for which there i,; experimental support include: I) 
metabolic dysfunction and/or impaired vascular en-
~raftment due to long standing diabetes mellitus 
noK:~ I); 2) steroid treatment. that may have a detri-
mental effect on islet engraftment and/or function 
,:t2). was not used in the duster-islet patients. and was 
higher in the kidney-islet group than in liver-islet re-
cipients: 3) the immune barrier to islet acceptance 
might be lowered by the presence of a liver from the 
"ame donor \:13). Based on our data we favor the hv-
pothesis of the protective effect of the simultaneous li~­
er gmh and/or the detrimental effect of steroid treat-
ment. In addition. weight loss was observed during the 
first 2-:3 post-operative rna in aU patients receiving a 
duster-islet graft. The nutritional problem associat-
• -'0 to upper aodominal exenteration could also result 
in reduced insulin requirement in these patients. In 
addition. the native pancreas is removed in these pa-
fients who probably have less glucagon than the Type 
t diabetic patients. 
in conclusion. our results indicate that pancreatectomy 
induced diabetes represents a favorable setting for 
long-term successful function of islet cell grafts. Re-
jection is still a major factor limiting the clinical ap-
plication of islet transplantation in patients with Type 
I diabetes mellitus. although other factors such as 
Oiteroid treatment may contribute to deteriorate islet en-
graftment and/or function. 
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